What happens when the US FDA, European Commission and European Medicines Agency all get together?

Last week saw the annual bilateral talks get underway once again between the three key agencies with the continued ambition of achieving regulatory collaboration to protect public health and allow patients timely access to medicines.

Aside from multiple different facets of talks on and around covid-19, including the sharing of experience and common challenges, many other key topics were discussed over the two day meet.

One important area was the goal of expanding the current Mutual Recognition Agreement (MRA) of Good Manufacturing Practice (GMP) inspections. Following the milestone reached in July last year with the full implementation of the MRA for human medicines, the partners discussed the next steps, including the expansion into veterinary medicines and the consideration to include vaccines and plasma-derived products by July 2022.

As holders of GMP, GLP and GCP certifications for human medicinal products, and GMP certification for veterinary medicinal products, in addition to being FDA & SUKL audited, QUINTA-ANALYTICA applaud the move and are excited to see these ever-closer ties and collaborative codes of standards become global.

Additional News

  • 18 March 2024

    News from our newly opened clinic in Ostrava

    Our new Clinic in Ostrava (CZ) is gaining momentum step by step; therefore, we have some interesting news for you from the center of the action.

  • 19 December 2023

    Happy new year 2024

    As we bid farewell to 2023, it's time to express our deepest gratitude for the collaboration.

  • 4 December 2023

    Our new clinical unit in Ostrava comes to life

    It's a great pleasure to announce that after two years of hard work, the brand-new clinical unit in Ostrava with 36-beds capacity has been opened.